Effect of long-term enalapril therapy on cardiopulmonary exercise performance in men with mild heart failure and previous myocardial infarction

Medical Department, Central Hospital, Stavanger, Norway.

Forty-one men with documented myocardial infarction greater than 6 months previously were randomized to long-term (48 weeks) therapy with placebo or enalapril on a double-blind basis. All patients were receiving concurrent therapy with digitalis and a diuretic drug for symptomatic heart failure (functional class II or III). The mean age was 64 +/- 7.3 years and no patient suffered from exertional chest pain. Patients underwent maximal cardiopulmonary exertional chest pain. Patients underwent maximal cardiopulmonary exercise testing to exhaustion on an ergometer cycle nine times over the course of 48 weeks. Gas exchange data were collected on a breath by breath basis with use of a continuous ramp protocol. In the placebo group (n = 21), the mean (+/- SD) peak oxygen consumption (VO2) at baseline was 18.8 +/- 5.2 versus 18.5 +/- 5.5 ml/kg per min at 48 weeks (-1.4%, p = NS). In the enalapril group (n = 20), the corresponding values were 18.1 +/- 3.1 versus 18.3 +/- 2.6 ml/kg per min (+2.8%, p = NS). The mean VO2 at the anaerobic threshold for the placebo group at baseline study was 13.1 +/- 3.5 versus 12.8 +/- 2.1 ml/kg per min at 48 weeks (-2.2%, p = NS). The corresponding values for the enalapril group were 11.8 +/- 2.3 versus 11.8 +/- 2.4 ml/kg per min (+1.4%, p = NS). The mean total exercise duration in the placebo group at baseline study was 589 +/- 153 versus 620 +/- 181 s at 48 weeks (+5.4%, p = NS).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				B. S. Wessler, D. G. Kramer, J. L. Kelly, T. A. Trikalinos, D. M. Kent, M. A. Konstam, and J. E. Udelson Drug and Device Effects on Peak Oxygen Consumption, 6-Minute Walk Distance, and Natriuretic Peptides as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction Circ Heart Fail, September 1, 2011; 4(5): 578 - 588. [Abstract] [Full Text] [PDF]

				D. W. Kitzman Understanding Results of Trials in Heart Failure With Preserved Ejection Fraction: Remembering Forgotten Lessons and Enduring Principles J. Am. Coll. Cardiol., April 19, 2011; 57(16): 1687 - 1689. [Full Text] [PDF]

				D. W. Kitzman, W. G. Hundley, P. H. Brubaker, T. M. Morgan, J. B. Moore, K. P. Stewart, and W. C. Little A Randomized Double-Blind Trial of Enalapril in Older Patients With Heart Failure and Preserved Ejection Fraction: Effects on Exercise Tolerance and Arterial Distensibility Circ Heart Fail, July 1, 2010; 3(4): 477 - 485. [Abstract] [Full Text] [PDF]

				J. Abdulla, S. Z. Abildstrom, E. Christensen, L. Kober, and C. Torp-Pedersen A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction Eur J Heart Fail, December 1, 2004; 6(7): 927 - 935. [Abstract] [Full Text] [PDF]

				J. Abdulla, H. Burchardt, S. Z. Abildstrom, L. Kober, C. Torp-Pedersen, and On behalf of TRACE study group The angiotensin converting enzyme inhibitor trandolapril has neutral effect on exercise tolerance or functional class in patients with myocardial infarction and reduced left ventricular systolic function Eur. Heart J., December 1, 2003; 24(23): 2116 - 2122. [Abstract] [Full Text] [PDF]

				B. D. Lowes, M. Higginbotham, L. Petrovich, M. A. DeWood, M. A. Greenberg, P. S. Rahko, G. W. Dec, T. H. LeJemtel, R. L. Roden, M. M. Schleman, et al. Low-dose enoximone improves exercise capacity in chronic heart failure J. Am. Coll. Cardiol., August 1, 2000; 36(2): 501 - 508. [Abstract] [Full Text] [PDF]

				M. Eccles, N. Freemantle, and J. Mason North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure BMJ, May 2, 1998; 316(7141): 1369 - 1375. [Full Text]

				R. Garg, S. Yusuf, the Collaborative Group on ACE Inhibitor Trials, W. D. Bussmann, P. Sleight, A. Uprichard, B. Massie, B. McGrath, B. Nilsson, B. Pitt, et al. Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure JAMA, May 10, 1995; 273(18): 1450 - 1456. [Abstract] [PDF]